VivoSim Labs, INC. (VIVS) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.26

From 52W high−94.53%

Volume1.50M

Market cap$3.77M

P/E (TTM)—

P/S (TTM)33.6x

Div yield—

Key dataSep 18, 2026

Open

$0.26

From 52W high

−94.53%

Volume

1.50M

Market cap

$3.77M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

28.6

MomentumView details →

1D Return

−12.39%

YTD Return

−86.76%

SummaryUpdated Jun 1, 2026

VivoSim Labs, Inc. (NASDAQ:VIVS) is a biotechnology company founded in 2007 and headquartered in San Diego, California. The company went public in February 2012 and was formerly known as Organovo Holdings, Inc. before changing its name to VivoSim Labs in April 2025. VivoSim operates at the intersection of biotechnology and advanced manufacturing, developing innovative 3D tissue technologies for drug development and therapeutic applications. The company has evolved from a pure-play bioprinting technology provider to a clinical-stage biotechnology company with both platform technology offerings and proprietary drug candidates in development.

Ask drillr about VivoSim Labs, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

21.5x

P/S (TTM)

33.6x

P/B (TTM)

−1.6x

ProfitabilityView details →

Gross Margin

−134.82%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

525.92%

ROA (TTM)

−320.72%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−21.13%

EPS YoY

—

FCF YoY

+2.95%

Revenue CAGR 3Y

−29.26%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−12.39%

YTD Return

−86.76%

1Y Return

−94.22%

RSI (14)

28.6

vs 50D SMA

−36.97%

vs 200D SMA

−82.31%

Capital & dividendView details →

Debt/Equity

−0.13x

Current Ratio

1.70x

Quick Ratio

1.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.25

EPS Surprise

—

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

4.73%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

112000.00

Net Income (TTM)

−12.34M

Op. CF (TTM)

−10.10M

Next earningsNov 5, 2026 →

Latest newsMore news →

VivoSim Labs unveiled new NAMkind drug toxicity data at EUROTOX 2026 in Vienna, demonstrating predictive superiority in liver and gastrointestinal safety across small molecules and ADCs.4d ago

VivoSim Labs, Inc. received a notice from NASDAQ on August 17, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share, and the company has until February 16, 2027, to regain compliance.31d ago

Similar companies

Jupiter Neurosciences, Inc.JUNS BioRestorative Therapies, Inc.BRTX Revelation Biosciences, Inc.REVB PMGC Holdings Inc.ELAB Cadrenal Therapeutics, Inc. Common StockCVKD Mustang Bio, Inc.MBIO Find similar companies →

Latest newsMore news →

VivoSim Labs unveiled new NAMkind drug toxicity data at EUROTOX 2026 in Vienna, demonstrating predictive superiority in liver and gastrointestinal safety across small molecules and ADCs.4d ago VivoSim Labs, Inc. received a notice from NASDAQ on August 17, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share, and the company has until February 16, 2027, to regain compliance.31d ago